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ABSTRACT
Although iron is essential for living organisms to survive, its reactive properties require strict regulation in order to prevent toxic effects.
Hepcidin, a liver produced peptide hormone, is thought to be the central regulator of body iron metabolism. Its production is mainly
controlled by the erythropoietic activity of the bone-marrow, the amount of circulating and stored body iron, and inflammation. Recent
reports, however, provide new hypotheses on how hepcidin might exert its regulatory function. Although hepcidin was first discovered in
human urine and serum, most of our understanding of hepcidin regulation and action comes from in vitro and mice studies that often
use hepcidin mRNA expression as a read out. The difficulties in carrying out studies in humans have mostly been due to the lack of
suitable hepcidin assay. The recent development of assays to measure hepcidin in serum and urine has offered new opportunities to
study hepcidin regulation in humans. However, for the moment, only a small number of laboratories are able to perform these assays.
The aim of this review is to discuss insights into hepcidin regulation obtained from recent clinical studies in the light of findings from
in vitro and mice studies. Ongoing studies in humans should provide us with more information on the etiology of iron metabolism dis-
orders in order to create new therapeutic strategies and improve differential diagnosis protocols for these diseases.
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PROGRESS IN HEMATOLOGY
Introduction
Body iron metabolism is based on a highly efficient system of
iron conservation and recycling by which only a part of the daily
need is replaced by duodenal absorption (Figure 1A).
Maintenance of body iron homeostasis requires mechanisms to
control uptake and mobilization from stores to meet erythropoi-
etic needs and to scavenge previously used iron. Therefore, the
communication between cells that consume iron and cells that
acquire and store iron must be strictly regulated.2 Duodenal
enterocytes absorb iron from the diet, where it is mostly present
as ferric Fe3+ or as heme (Figure 1B). After reduction on the api-
cal surface of the enterocytes by duodenal cytochrome-b
(Dcytb), iron enters the cell by divalent metal transporter-1
(DMT-1). Heme is reported to be absorbed by a recently identi-
fied receptor heme-carrier protein-1 (HCP-1)3 and released from
iron by heme oxygenase-1 (HO-1). Once in the cell, iron is
stored by ferritin and released into the plasma by the cellular
iron exporter ferroportin when there is high body demand. After
oxidation by ferroxidase hephestin (intestinal cells) or cerulo-
plasmin (nonintestinal cells), iron is loaded onto transferrin for
transport in the plasma where it is picked up by TfR1 on the cell
surface of cells in need of iron. Besides dietary uptake, iron is
recycled from senescent erythrocytes by macrophages (Figure
1C). Also here, HO-1 plays an important role in extracting iron
from heme in the cytosol while involvement of DMT-1 is sus-
pected but not proven.4 A recent review on cellular iron uptake,
storage and export is given by Dunn et al.5
The discovery of hepcidin
Although hepcidin was first discovered in human urine and
serum, most data on hepcidin expression, regulation, structure
and function were obtained by in vitro approaches and studies in
mice. Hepcidin was initially isolated from plasma ultrafiltrate6
and named liver-expressed antimicrobial peptide (LEAP-1).
Around the same time, it was isolated from human urine and
named hepcidin after its hepatic origin and bactericidal effect in
vitro.7 The development of severe iron overload8 by knocking out
the gene in mice suggested that hepcidin is involved in iron
metabolism, whereas this key role in regulation was underlined
Acknowledgments: we would like to thank our colleagues at the Department of Clinical Chemistry for their contribution to the development of the SELDI-TOF
MS-based hepcidin assay, especially Coby Laarakkers and Arnoud Loof of the SELDI-TOF MS facility at the Department of Hematology. We also thank Gert
Vriend and Hanka Venselaar (the Centre for Molecular and Biomolecular Informatics, CMBI, Nijmegen Centre for Molecular Life Sciences, NCMLS, Nijmegen)
for creating the structural models of hepcidin and their suggestions and advice.
Manuscript received May 9, 2007. Manuscript accepted September 3, 2007.
Correspondence: Dorine W. Swinkels, Department of Clinical Chemistry 441, Radboud University Nijmegen Medical Centre, P.O. Box 9101 6500 HB
Nijmegen, The Netherlands. E-mail: d.swinkels@akc.umcn.nl
The online version of this article contains a supplemental appendix.
Hepcidin: from discovery to differential diagnosis
haematologica | 2008; 93(1) | 91 |
by the discovery of hepcidin mutations in patients.9 The
newly discovered peptide was found to be regulated by
inflammation, iron stores,10 hypoxia and anemia.11
Structure of hepcidin
The human hepcidin gene (HAMP; OMIM 606464),
located on chromosome 19q13.1, encodes a precursor pro-
tein of 84 amino acids (aa). During its export from the
cytoplasm, this full-length pre-prohepcidin undergoes
enzymatic cleavage, resulting in the export of a 64 aa pro-
hepcidin peptide into the ER lumen.12 Next, the 39 aa pro-
region peptide is probably posttranslationally removed by
a furin-like proprotein convertase7 resulting in mature
bioactive hepcidin-25 (25 aa form). In human urine, Park
et al. also identified hepcidin-22 and hepcidin-20, which
are N-terminally truncated iso-forms of hepcidin-25.7
Recently we confirmed that in addition to hepcidin-25,
the 20 aa iso-form is detectable in both human urine and
serum, while the 22 aa iso-form can only be detected in
urine.13 These results support the hypothesis that the 22 aa
peptide is merely an urinary degradation product of hep-
cidin-25.14 Structural analysis of human synthetic hepcidin
by NMR spectroscopy revealed that this 8 cysteine-con-
taining peptide forms a hairpin-shaped molecule with a
distorted b-sheet which is stabilized by four disulfide
bridges between the two anti-parallel strands.15 One of the
disulfide bridges is located in the vicinity of the hairpin
loop which points to a possible crucial domain in the
activity of the molecule15 (Figure 2). The high cysteine
content of the molecule is highly conserved among other
species.7 Structure-function in vivo (mice) and in vitro stud-
ies on synthetic hepcidin have shown that the iron regu-
lating bioactivity is almost exclusively due to the 25 aa
peptide, suggesting that the five N-terminal amino acids
are essential for this activity.17,18 In vitro experiments have
shown that especially human hepcidin-20 exerts anti-bac-
terial and anti-fungal activity in a concentration range 10-
fold higher than that measured in healthy individuals.6,7
Therefore, it is not clear whether in vivo hepcidin levels
can reach values in which it can be anti-microbial, or
whether this function is of biologic importance or only
rudimentary in its evolutionary origin.19 A recent report on
inductively coupled plasma-mass spectrometry (ICP-MS)
on human hepcidin extracted from urine samples showed
co-purification of at least one iron molecule with hep-
cidin.20 Modeling of a best-fit 3D structure of hepcidin
with iron demonstrated significant differences from the
previously reported synthetic hepcidin model.15 These
new findings suggest a conformational polymorphism for
hepcidin as a regulatory mechanism for iron uptake as
part of its role as regulator of iron homeostasis. 
Mechanism of hepcidin activity
Recently, hepcidin was reported to bind to the trans-
membrane iron exporter ferroportin21,22 which is present
on macrophages and the basolateral site of enterocytes
(Figure 1B and C), but also in hepatocytes. It has been
demonstrated in vitro that hepcidin induces the internaliza-
tion and degradation of ferroportin.23 It is not yet known
whether structural properties such as amino terminal Cu
and Ni binding (ATCUN) motifs in the hepcidin-25 mole-
cule play a role in this process24 (Figure 2). For cellular iron
export, the cell depends on ferroportin, as originally
demonstrated in zebra fish.25 By diminishing the effective
number of iron exporters on the membrane of enterocytes
or macrophages, hepcidin suppresses iron uptake and
Figure 1. Iron uptake and recycling. A.
Most of the utilized body iron is recycled
from senescent erythrocytes by
macrophages, and returned to the bone
marrow for incorporation in erythroid pre-
cursors. The liver and reticuloendothelial
macrophages function as major iron
stores. 1-2 mg of iron is absorbed and lost
every day. Only duodenal absorption is reg-
ulated by transporters such as DMT1 and
HCP1, whereas iron loss occurs passively.
The liver-produced peptide hepcidin con-
trols the plasma iron concentration by
inhibiting iron export by ferroportin from
enterocytes (B) and macrophages (C). This
means that an increased hepcidin produc-
tion leads to a decrease in plasma iron
concentrations. Hepcidin expression is reg-
ulated by body iron stores, inflammation,
erythroid iron demand, and hypoxia via
regulation pathways involving expression
of HFE, TfR2, TfR1 and HJV genes. Details
are discussed in the text and in figure 3.
DMT1: divalent metal transporter 1; Hb:
hemoglobin; HO: heme oxygenase; NTBI:
non-transferrin bound iron; Tf: transferrin;
Cp: ceruloplasmin; HCP1: heme carrier
protein 1; DcytB: duodenal cytochrome B.
Adapted and reproduced with permission
from Swinkels et al. Clin Chem 2006.1
B
A
C
Bone marrow
~300 mg
Erythrocytes
~1800 mg
Fe - Transferrin
~3mg
Macrophages ~600 mg
Iron uptake
1-2 mg/day
HO
NTBI
Ferroportin
Ferroportin
Ferritin
Ferritin
Hephaestin
Liver
Increased erythroid demand
Hypoxia
Fe
Infiammation
Hepcidin
Iron loss
1-2 mg/day
HFE HJV
TfR1/TfR2
20-25
mg/day
E.H.J.M. Kemna et al. 
| 92 | haematologica | 2008; 93(1)
release respectively. This is in line with the phenotype of
ferroportin disease where iron accumulation is observed
mainly in macrophages often combined with anemia.26
Besides this systemic liver hepcidin controlled reduction
of iron uptake and release, there is also evidence for local
production of hepcidin by macrophages,27 fat cells28 and
cardiomyocytes.29 These findings suggest hepcidin is
involved in different regulatory mechanisms to control
iron imbalance. 
Hepcidin at the nexus of various regulatory pathways 
At present, four putative upstream regulatory pathways
are generally thought to control liver hepcidin production:
(i) iron store-related regulation (ii) erythropoietic activity
driven regulation (iii) inflammation related regulation, and
(iv) a mandatory signaling pathway. All are found to inter-
act with liver cells to initiate the production of sufficient
hepcidin for correct maintenance of iron homeostasis.30-35
A model of pathways involved in hepcidin regulation that
builds upon recent findings mainly from mice studies and
in vitro cell culture studies is shown in Figure 3. Three rel-
evant sites involved in hepcidin regulation are presented:
kidney, bone marrow and liver cells. Notably, the iron
efflux regulation in macrophages by hepcidin and skeletal
muscles expressing high levels of hemojuvelin are not
shown. A detailed discussion of each of these 4 pathways
and the transcriptional regulation of hepcidin can be
found in Online Supplemental text file 1. 
Hepcidin kinetics 
After hepcidin is secreted into the circulation by the
hepatocytes it eventually exits the body in the urine. Its
effect on the decrease in serum iron levels in mice
appeared to take place within 4 hours in a dose-depend-
ent way that was sustained for more than 48 hours.17
Indirect hepcidin inductions by IL-6 or LPS in humans dis-
played the same fast response in urinary hepcidin excre-
tion,36,37 thereby acting like an acute phase protein with a
peak value after 6 hours, followed by a steady decrease.
Oral iron administration for 3 days in healthy human vol-
unteers showed a significant increase in urinary hepcidin
after 24 hours which disappeared over the following days
despite the iron intake. The peak urine value suggests a
fast clearance of hepcidin from the circulation, with a par-
adoxical sustained inhibitory effect on iron uptake, shown
by the iron parameters which remained unchanged over
the following days.36
The fast appearance of hepcidin in urine demonstrates
the exceptional characteristics of this peptide. So far,
tubular dysfunction, or even reported tubular expression38
of hepcidin as a causative factor in hepcidinuria, have not
yet been studied. 
Hepcidin: from mice to men
Although highly homologous hepcidin genes have also
been identified in many vertebrates, including rodents like
mice and rats, several species of fish, dogs and pigs, it
should be noted that in mice two paralogous genes have
been found from which only Hepc1 appears to be
involved in iron metabolism.39,40 As previously described,
mice have provided a useful animal model to identify and
trace the pathways in iron metabolism, but these differ-
ences at the genetic level of hepcidin mean that care must
be taken when considering results on hepcidin obtained in
mice in studies on humans. Similarly, although in vitro sys-
tems allow a broad spectrum of intervention, any similar-
ity to the human in vivo situation is limited. Therefore,
measurement of circulating levels of hepcidin in man is
important to increase our knowledge on the role of hep-
cidin in different pathological conditions (Supplemental
Figure 2. Molecule structure of human synthetic
hepcidin-25. Front: overview of the structure of
hepcidin-25. Distorted b-sheets are shown as grey
arrows, and the peptide backbone is colored gray.
The disulfide bonds are colored yellow, highlighting
the position of an unusual vicinal bond between
adjacent cysteines at the hairpin turn. Positive
residues of Arginine (Arg)and Lysine (Lys) are pic-
tured in blue, the negative residue of Aspartic acid
(Asp) in red, and the Histidine containing amino
terminal Cu2+- Ni2+ (ATCUN)-binding motif in the N-
terminal region is colored green. Background: hep-
cidin-25 molecule displayed with solvent accessi-
ble surface that illustrates the amphipathic struc-
ture of the molecule. The molecule is colored gray,
except for the side-chains of positive (blue) and
negative (red) residues. Molecular graphics creat-
ed with YASARA16 (www.yasara.org) and PovRay
(www.povray.org), with coordinates and factors
obtained from the Protein Data Bank
(www.rcsb.org; PDB file code 1M4F). 
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Table 1, panel A). More specifically, these findings might
add to the definition of hepcidin as a differential diagnos-
tic tool and therapeutic target in human disease. 
Assessment of urinary and serum hepcidin in humans
Until recently, few investigative tools were available to
detect hepcidin in human studies. Hepcidin mRNA
expression is mostly preferred in animal and cell culture
studies, but is obviously used very sporadically in human
studies because of the need of invasive sampling.
Immunochemical methods based on the use of specific
anti-hepcidin antibodies, such as in immuno-histochemi-
cal tissue staining, SDS-PAGE and Western Blot41,42 are
problematic mainly because of the limited availability of
suitable antibodies. This can be attributed to the small
size of hepcidin, the compact and complex structure of
the molecule, and the highly conserved sequence among
species, complicating the elicitation of an immune
response in host species. We will briefly describe and dis-
cuss the assays currently available to measure (pro)hep-
cidin in serum and/or urine.
Antibody-based hepcidin assay
To our knowledge, only one antibody-based dotblot
assay has successfully been used so far to semi-quantify
hepcidin in urine.36 With the use of cation exchange chro-
matography, peptides are extracted from urine and resus-
pended and immobilized on a vinyl membrane. Hepcidin
is quantified by Chemiluminescence detection using rab-
bit anti-human hepcidin primary antibodies,41 and goat
anti-rabbit horseradish peroxidase as a secondary anti-
body. Hepcidin quantity in each sample is normalized
using urinary creatinine concentrations. Given the lack of
a control for hepcidin losses in the pre-analytical phase of
the analysis, such as in the protein extraction and resus-
pension steps, this assay could be considered semi-quan-
titative. The limited availability of mostly non-commer-
cially made antibodies makes the optimization of anti-
body-based assays with guaranteed specificity difficult
to achieve. On the other hand, a hepcidin ELISA will
greatly enhance the accessibility of the analysis, but it is
not likely to discriminate between the different isoforms
of hepcidin. Besides bioactive hepcidin, the measure-
Figure 3. Model of pathways involved in hepcidin regulation. The three active regulation pathways (erythropoietic activity derived regu-
lation, iron store regulation, and inflammation regulation) and a mandatory signaling pathway that together control the hepcidin produc-
tion in the liver cell. Erythropoiesis is controlled by hypoxia-induced erythropoietin production or the kidney. The bone marrow commu-
nicates by a still unknown factor that is likely to interfere with the iron store regulation. This store regulation involves the circulating
amount of transferrin bound iron that competes with HFE in binding to TfR1 hereby promoting formation of the TfR2/HFE complex as
an inducer of hepcidin production. The direct influence of intracellular iron from the labile iron pool on hepcidin regulation is not yet
clear. The inflammation regulatory pathway is mainly induced by IL-6 and is thought to act more dominant regardless of the activity of
the other pathways. The HJV controlled BMP/SMAD signaling pathway appears to be mandatory for the activity of the store and erythro-
poiesis derived regulation. The metabolic syndrome candidate genes USF1 and 2 are in direct control of the HAMP gene, suggesting a
link between lipid, glucose, and iron metabolism. pO2: partial oxygen pressure; HIF: hypoxia inducible factor; CBP: CREB binding protein;
EPO: erythropoietin; HNF: hepatic nuclear factor; TfR: transferrin receptor; sTfR: soluble TfR; HFE: hemochromatosis iron protein; b2M:
b-2 microglobuline; HJV: hemojuvelin; sHJV: soluble HJV; BMP: bone morphogenetic protein; BMPR: BMP receptor; P: phosphate; SMAD:
mothers against decapentaplegic homologue (Drosophila); IL: interleukin; IL-6R: interleukin-6 receptor; gp: glycoprotein; JAK: Janus
kinase; STAT: signal transducer and activator of transcription; TGF: transforming growth factor; USF: upstream stimulation factor; E: E-
box; HAMP: hepcidin anti-microbial peptide gene; CE-9: conserved element 9. 
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ment of its precursor pro-hepcidin has been reported
with the use of a commercially available ELISA kit that
uses antibodies directed against the pro-peptide region of
hepcidin.43 However, the diagnostic use of this assay is
controversial because of the lack of clear correlations
with hepcidin13,37 and other iron related parameters.44,45
Significant concentration differences only have been
reported in ferroportin disease46 or in combination with
end-stage renal disease (ESRD).47
Mass spectrometry-based hepcidin assay
Recently we described a surface-enhanced laser desorp-
tion/ionization time-of-flight mass spectrometry (SELDI-
TOF MS)-based assay that detects the three known iso-
forms of hepcidin.48 More recently improvements have
made this technique also suitable for measuring hepcidin-
25 in serum.13 Importantly, the procedure is quick to carry
out but difficult to robotize due to the on-spot procedure.
The latest improvement in the application includes both a
procedure to prevent hepcidin losses during sample prepa-
ration and the introduction of a hepcidin analogue as
internal standard, which allows sensitive quantification of
hepcidin in both serum and urine samples (D. Swinkels and
C. Laarakkers, unpublished results).
The potency of MS-based hepcidin analysis has been
underlined in other recent reports.49,50 Tomosugi and co-
workers49 reported serum hepcidin measurements with
the use of SELDI-TOF MS, but with the use of diluted
serum samples and a bioprocessor. Compared to the
direct on-spot method described above, this application
allows the use of robotics. It uses synthetic human hep-
cidin-25 to construct an external standard curve, but since
it doesn’t use an internal standard it should be regarded as
semi-quantitative.49
Another report on serum hepcidin analysis uses liquid
chromatography tandem mass spectrometry (LC-
MS/MS)50 with a non-hepcidin related internal standard.
Both LC-MS/MS and SELDI-TOF MS still need highly
specialized equipment, and therefore do not readily
improve accessibility. 
Comparative studies, the use of uniform internal stan-
dards, and accuracy adjustment of all techniques available
to date might increase the comparability of results in the
future. For the moment, mass spectrometry-based hep-
cidin measurements in serum and urine seem to be an
attractive option to semi-quantify serum and urine hep-
cidin levels in clinical studies for research purposes in a
small number of laboratories around the world. 
A constant improvement in analytical techniques is
essential to accurately assess levels of hepcidin and its
isoforms in body fluids of different species, cell media
and cell contents. 
Insights from hepcidin measurements in humans 
The development and implementation of urinary and
serum hepcidin assays led to several clinical studies that
increased the existing knowledge on hepcidin levels in
physiologic and pathophysiologic states. These studies
will now be discussed in the light of previous related in
vitro approaches and analogous studies using mice as
model organisms. An overview is presented in the Online
Supplemental Table.
Pre-analytical factors and diurnal variation
First of all, evaluation of our MS-based hepcidin meas-
urements in human serum and urine samples revealed a
substantial influence of pre-analytical factors, especially
on urinary hepcidin, and a large diurnal variation in serum
hepcidin levels.13 Murphy et al.50 also found a large diurnal
variation. In mice, background influences like strain and
gender have been shown to substantially modulate liver
hepcidin mRNAs.51 In a small set of samples, Murphy et
al.51 found no major differences between serum concentra-
tions from normal males and females,50 which agrees with
our findings in a different control group for both serum
and urine values.13
Hepcidin regulation
The involvement of hepcidin in the induction of hypo-
ferremia by inflammation was translated from mice to
human studies after the introduction of the urinary dot-
blot and the SELDI-TOF MS assays, which also demon-
strated the existence of the highly responsive LPS- IL-6-
hepcidin axis as a link between innate immunity and iron
metabolism.36,37,41
Erythropoietic activity appeared to be a strong regulator
of hepcidin levels, i.e. erythropoietin that stimulates ery-
thropoietic activity has been shown to down-regulate
liver hepcidin mRNA-expression in mice.52 However, in
the absence of erythropoietic activity, hepcidin expression
is no longer suppressed.32 The strong inverse association
between erythropoietic drive and hepcidin production
was also observed in several patients with congenital
chronic anemias,53-56 which are characterized by low uri-
nary hepcidin levels.
Hepcidin in hereditary hemochromatosis
Both SELDI-TOF MS and the dotblot method were
used to measure hepcidin levels in juvenile cases of
hemochromatosis, and were found to be extremely
low.13,53,57,58 Less severely decreased, but still clearly low uri-
nary hepcidin levels, were found in patients with TfR2
mutations using the urine dotblot method.59 Similarly,
decreased mRNA levels were seen in liver biopsies of
HFE-KO or deficient mice and humans,60,61 whereas levels
ranging to almost normal values in serum and urine were
found in HFE-hemochromatosis patients.13,41 Although the
mechanism behind this observed variability in hepcidin
values especially in classic hemochromatosis is still not
completely clear, the presence of iron overload at presen-
tation and of the increased erythropoiesis with phleboto-
my treatment are likely to contribute (B. van Dijk and D.
Swinkels, unpublished observations). 
In ferroportin disease, hepcidin concentrations appear
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to vary with the sequence variations of the gene and the
way they influence the activity of the ferroportin pro-
tein.18,62 Patients with 162delVal and N144H alterations in
ferroportin were reported to have high hepcidin levels
with a loss in function of ferroportin,13,53 whereas in cases
of other variants with a gain of function the hepcidin lev-
els are normal but relatively too low for the degree of iron
loading in these patients.13,63
Hepcidin in secondary iron overload
The dotblot and SELDI-TOF methods were used to
observe low/normal hepcidin levels for the degree of iron
load in thalassemic patients,13,53-56 which agree with levels
of expression found in mice64,65 and are thought to be the
cause of increased iron uptake. Most of these patients are
transfusion dependent, thereby aggravating the iron bur-
den.66 The lower hepcidin levels mostly found in tha-
lassemia intermedia compared with thalassemia major
can be attributed to the higher degree of erythropoiesis
expansion and lower degree of iron burden of the inter-
media form.56
Hepcidin and renal anemia
SELDI-TOF MS measurement of serum hepcidin in
end-stage renal disease patients showed accumulated
hepcidin levels that could be partly reduced by hemodial-
ysis.49 This accumulation suggests hepcidin contributes to
the pathogenesis of renal anemia. Much of the etiology
behind this anemia is still unclear, but it is thought to be
caused by reduced EPO production and is, therefore,
mostly treated by administration of human recombinant
erythropoietin (EPO) in combination with oral iron. Other
factors, such as hyperparathyroidism, aluminum toxicity,
systemic inflammation, and impaired iron metabolism,
seem to be of minor importance.67
Differential diagnosis and therapeutic implications
The outcomes of the studies in humans described above
have implications for the use of hepcidin as a diagnostic
and therapeutic tool. These are based on small series,
sometimes even on only a few cases. This shows that
large scale clinical validation is still needed to prove the
power of hepcidin in differential diagnosis. First, the circa-
dian rhythm observed for serum might require sampling
protocols for hepcidin analysis that include standardiza-
tion of time of blood withdrawal, similar to that for the
assessment of serum iron levels or transferrin saturation. 
Second, recognition of iron deficiency anemia (IDA) in
the context of anemia of chronic disease (ACD) is current-
ly performed with routine biochemical parameters, such
as transferrin saturation, ferritin, CRP and, less often, sol-
uble TfR (sTfR), zinc protoporphyrin and new erythro-
cyte indices. Each have their own disadvantages.1,68,69 In
contrast to increased levels of hepcidin in ACD, both in
vitro iron deficiency11 and classic IDA in humans are asso-
ciated with low hepcidin levels13,41 which makes hepcidin
a potential marker for detection of IDA in ACD.1
However, studies in anemic patients suffering from dis-
eases such as rheumatoid arthritis, inflammatory bowel
diseases, cancer, and end-stage renal disease are needed to
validate the potency of hepcidin measurements under
these conditions. 
Third, hepcidin analysis might have a role as a screen-
ing, prognostic and monitoring test for hereditary
hemochromatosis (HH), provided that abnormalities in
liver functions,70 inflammation and a short interval
between sample collection and phlebotomy are excluded.
As shown in Supplemental Table 1, panel B, at presentation
urinary hepcidin levels are low or even undetectable in all
cases of juvenile hemochromatosis and likely to be mod-
erately decreased or low for the increased iron stores in
TfR2 and HFE sequence variants. In our opinion, assess-
ment of hepcidin values might be instrumental in deter-
mining the likelihood of candidate genes involved in
patients with non-HFE HH. This might reduce the work-
load and costs of the slow screening procedures for
sequence variations in the multiple genes responsible for
hemochromatosis.1
Fourth, in iron loading anemias such as thalassemia,
studies have suggested hepcidin or hepcidin/ferritin index
values at the lower end of the reference range to be a
result of suppressed hepcidin production due to high and
less effective erythropoietic activity.71 These findings may
be relevant in the search for non-invasive measures of iron
burden and improved therapeutic interventions for these
often congenital diseases.
Finally, determination of hepcidin levels might prove
useful in predicting a response to EPO and iron treatment
in patients with chronic disease anemias, as well as in the
monitoring of EPO treatment. Until now, predicting how
patients will react to EPO treatment is complicated by the
co-existence of several factors that contribute to anemia,
such as inflammatory activity and liver toxic therapy.
Further studies are warranted to determine hepcidin levels
in chronic kidney disease, end-stage renal disease, on
hemodialysis and EPO and/or iron treatment in relation to
iron and inflammatory status and blood counts. These
studies will lead to novel diagnostic and improved thera-
peutic strategies in patients treated with EPO. 
Conclusions
The regulation of body iron, an essential but also toxic
element is strictly controlled by a small peptide hormone
hepcidin. This principal liver-produced peptide is charac-
terized by its unique anti-microbial structural and func-
tional properties which places it at the crossroads
between innate immunity, host defence and iron metabo-
lism. Body iron levels, inflammation and erythropoietic
activity appear to be the main regulators of hepcidin.
Recent research has provided new insights into the main
regulatory pathways but also into other networks that
interact in hepcidin synthesis. Altogether, the body iron
homeostasis network with hepcidin at the centre appears
to be more complex than was originally thought.
E.H.J.M. Kemna et al. 
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Constant improvements in hepcidin assays for serum
and urine will be essential to translate results obtained
from mice and in vitro studies to humans. A wider knowl-
edge of hepcidin regulation will provide us with novel
tools for differential diagnosis, therapeutic regimes and
monitoring of disorders of iron metabolism.
We apologize to all our colleagues whose work we
could not cite due to limitations of space. 
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